Oxford BioDynamics PLC OBD appoints Dr Bartu Ahiska
13 June 2019 - 4:01PM
RNS Non-Regulatory
TIDMOBD
Oxford BioDynamics PLC
13 June 2019
13 June 2019
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics appoints Dr Bartu Ahiska as Senior Vice
President (Commercial)
Oxford BioDynamics Plc (AIM: OBD), a biotechnology company
focused on the discovery and development of epigenetic biomarkers
based on regulatory genome architecture, for use within the
pharmaceutical and biotechnology industry, announces that it has
appointed Dr Bartu Ahiska as Senior Vice President (Commercial), to
spearhead the commercialisation of the Group's EpiSwitch(TM)
technology platform.
Bartu Ahiska is an experienced entrepreneur, IP strategist and
technology driver with experience in several fields including
medical engineering, biologics, computing and graphics. He joins
OBD from the Knight Cancer Early Detection Advanced Research Centre
(CEDAR) at Oregon Health & Science University (OHSU) in
Portland, Oregon, where he has been Innovation, IP &
Commercialisation manager since 2016. He was a co-founder and
remains a Non-Executive Director of Trogenex Inc in San Diego, CA,
and was COO and CEO of cloud-computing company Approxy before its
acquisition by Numecent. He holds a D Phil in Computational
Genomics from Oxford University (for which he secured a
fully-funded EPSRC scholarship and Bill & Melinda Gates
Foundation funding) and a MEng and MA in Information and Electronic
Engineering from Cambridge University.
Bartu joins OBD's expanding commercial team and will work
closely with both Glen Ferguson, who was appointed Senior Vice
President (USA) in March 2019, and the rest of the Group's
executive management team.
Christian Hoyer Millar, Chief Executive Officer of Oxford
BioDynamics, said:
"Bartu Ahiska has an exceptional track record as an entrepreneur
in the creation and commercialisation of intellectual property, as
well as an impeccable academic background. We are excited to have
him join the OBD team and look forward to working with him for the
benefit of our shareholders."
-ENDS-
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
FTI Consulting
Financial Public Relations
Adviser
Brett Pollard
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for
Enterprise: Innovation. The Queen's Awards for Enterprise are the
most prestigious awards for UK businesses.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABLGDLXXBBGCD
(END) Dow Jones Newswires
June 13, 2019 02:01 ET (06:01 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024